Revision Skincare has entered a strategic partnership with RVL Pharmaceuticals, the owner of UPNEEQ, the first and only FDA-approved prescription eye drop for the treatment of acquired ptosis (low-lying lids) in adults.
WHO: Revision Skincare is a leading medical-grade professional skincare brand. The brand's formulation philosophy is to develop clinically validated, high-potency, transformative skincare, integrating an approach that delivers maximum efficacy while maintaining long-term skin health. Based in Irving, Texas, Revision Skincare is sold in more than 16 countries.
RVL Pharmaceuticals is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution) 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. UPNEEQ is believed to be the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
WHY: This strategic partnership aligns two game-changing brands to offer more accessible solutions to aesthetic patients and providers nationwide with shared values and visions for business growth and an expanding footprint.
IN THEIR OWN WORDS: "We know that RVL Pharmaceuticals has a lot of choices when it comes to commercial partnerships. We are excited to join this mission with RVL to offer breakthrough patient solutions," said Maria Carell, CEO and President, Revision Skincare.
"We are thrilled to partner with Revision Skincare! Their strong history of innovation and passion for skin health aligns with our core directive around ocular medical aesthetics," said Brian Markison, CEO, RVL Pharmaceuticals.
DETAILS:
